SlideShare une entreprise Scribd logo
1  sur  38
A  SEMINAR ONTRANSPORT  ACROSS  CACO-2 MONOLAYER GUIDED BY:BY: PATEL AKSHAY DR.MANISH PATEL               M.PHARM- 1(ph’ceutics)    (head of department)                 ROLL NO-05  Department of Pharmaceutics NOOTAN PHARMACY COLLEGE,VISNAGAR
content ,[object Object]
Intestinal absorption
Intestinal absorption models
Caco-2 monolayer
Caco-2 cell culture
Characterization of cell culture
Permeability assay
Permeability assay validation
Biological and analytical consideration
References,[object Object]
Intestinal Absorption: Biology Enterocite biology: Absorptive cells of intestine, function is terminal digestion and absorption of water and nutrients from the intestinal lumen. Polarised monolayer :          -Apical: microvilli face the interior of gut and increase 	the surface available for absorption by>1000 fold          -Basal: faces away from gut in contact with 	extracellular matrix.
Intestinal transport mechanism: Major types ,[object Object]
Transcellular: For most lipophilic drugs. This route involves either passive diffusion, carrier mediated or receptor mediated endocytosis,[object Object]
B: carrier mediated absorption at apical and basolateral membranes;
C: active efflux transporter on apical membrane, acting during absorption;
D: active efflux transporter on apical membrane, offering an additional route for drug clearance from the circulation;
E: intracellular metabolising enzymes localized inside the enterocytes, possibly combined with an active efflux transporter on apical and basolateral membranes. ,[object Object]
Intestinal absorption models 1Animal studies (Rat) - Very low throughput 2	Insitu intestinal models  - Very low throughput, expensive  	Human/rat primary intestinal cells -Short functional life, lose differentiation characteristics 3	Intestinal Epithelial Barrier Models ,[object Object]
HT 29 Cells: Colon carcinoma, cultured with galactose, express mucus producing goblet cells differenciation
Caco-2 Monolayer: Human colorectal adenocarcinoma Cell monolayer,[object Object]
Caco-2 cell monolayers spontaneously differentiate to express morphological and functional characteristics of mature small-intestinal enterocytes. The differentiated monolayers are polarized, with microvilli on the apical side.,[object Object]
Four times higher in transepithelial resistance compared to HT 29-cell monolayer
It expresses various drug metabolizing enzymes like, aminopeptidase, esterase, and sulfatase.,[object Object]
Dose not produce the mucus and unstirred water Observed in the intestine
No P-450 drug metabolizing enzyme activity has been reported
Expensive method
Time consuming as 21 days required for full cell differentiation
The necessity of LC / MS or HPLC for quantitation
Influence of P-gp is difficult to estimate,[object Object]
CaCO2 Culture media
Transport media
Characterization of cell monolayer Cellular Architecture (Microvilli, Junctional Complexes) Barrier Function ( Lucifer Yellow Permeability, TEER) Differentiation Markers (Alkaline Phosphate, Brush-Border Peptidases) Transporters (P-Glycoprotein, PepT1, Amino acid Transporter, glucose)
1.CELLULAR ARCHITECTURE 3 Days 21 Days
2.BARRIER FUNCTION ,[object Object],Measurement of the integrity of the caco-2 cell monolayer After washing the cell monolayer with 37°C tempered D-PBS (with Ca2+, Mg2+) (Dulbecco's Phosphate Buffered Saline), 1600 μl transport medium was added into the apical and 2800 μl transport medium was added into the basal compartment.  Allow for equilibrium for 60 min in the cell culture incubator.
4. The measurement chamber was tempered to 37°C with transport medium before the measurement. For the post-experimental TEER measurement, the withdrawn volume in the apical compartment was replaced with transport medium before TEER was measured. 5.Caco-2 monolayer with TEER values exceeding 250 Ωcm2 were used for transport experiments. 6. Background TEER may be recorded in wells without cell monolayers, and can be subtracted from the raw TEER values with cells.
B. Lucifer yellow (LY) rejection: Rinse the monolayer three times with 300 µL HBSS ( Hank’s buffer saline solution) in the apical wells and 28 mL in the feeder tray. Add 300 µL of LY solution to each well in the filter plate (Apical Template). Add 600 µL HBSS to each well of a 24-well receiver tray (Basolateral Template). Assemble the filter plate and 24-well receiver plate and incubate for 1–2 hours at 37°C. Remove the filter plate from the receiver plate and place the receiver plate into a fluorescent plate reader. Determine the LY fluorescence using an excitation wavelength of 425-430 nm and an emission wavelength of 515-520 nm, 540 nm.
	Calculate the percent of LY rejection across the cell monolayer by measuring fluorescence in the receiver plate as compared to an ‘equilibrium’ standard.The standard plate should consist of 4 wells with 600 µL HBSS (blank) and 4 wells with 200 µL LY (100 µg/mL) + 400 µL HBSS (equilibrium samples)Calculate the LY rejection using the following equation:                                           LY Rejection=100%-%LY Passage

Contenu connexe

Tendances

alternative methods for dissolution.pptx
alternative methods for dissolution.pptxalternative methods for dissolution.pptx
alternative methods for dissolution.pptxanumalagundam sreekanth
 
Biopharmaceutical factors effecting bioavailability
Biopharmaceutical factors effecting bioavailabilityBiopharmaceutical factors effecting bioavailability
Biopharmaceutical factors effecting bioavailabilitySyed Rashed Faizan Mehdi
 
Formulation Approaches For Gastro Retentive Drug Delivery
Formulation Approaches For Gastro Retentive Drug DeliveryFormulation Approaches For Gastro Retentive Drug Delivery
Formulation Approaches For Gastro Retentive Drug DeliveryNaman Pant
 
Dissolution and drug release testing
Dissolution and drug release testingDissolution and drug release testing
Dissolution and drug release testingRoshan Bodhe
 
Self micro-emulsifying drug delivery system (SMEDDS)
Self micro-emulsifying drug delivery system (SMEDDS)Self micro-emulsifying drug delivery system (SMEDDS)
Self micro-emulsifying drug delivery system (SMEDDS)Himal Barakoti
 
Bioelectronic medicines
Bioelectronic medicinesBioelectronic medicines
Bioelectronic medicinesDurga Bhavani
 
Drug product performance
Drug product performanceDrug product performance
Drug product performanceVivekBihania
 
Biopharmaceutical system , methods of permeability , generic biologics, gener...
Biopharmaceutical system , methods of permeability , generic biologics, gener...Biopharmaceutical system , methods of permeability , generic biologics, gener...
Biopharmaceutical system , methods of permeability , generic biologics, gener...Siddhapura Pratik
 
Invitro invivo insitu method
Invitro invivo insitu methodInvitro invivo insitu method
Invitro invivo insitu methodGURUPRASAD S
 
Study submission of Bioequivalence and Drug review Process, BCS (BIOPHARMACEU...
Study submission of Bioequivalence and Drug review Process, BCS (BIOPHARMACEU...Study submission of Bioequivalence and Drug review Process, BCS (BIOPHARMACEU...
Study submission of Bioequivalence and Drug review Process, BCS (BIOPHARMACEU...Naveen Balaji
 
Pulmonary drug delivery system [PDDS]
Pulmonary drug delivery system [PDDS]Pulmonary drug delivery system [PDDS]
Pulmonary drug delivery system [PDDS]Sagar Savale
 
Investigational New Drug Application
Investigational New Drug ApplicationInvestigational New Drug Application
Investigational New Drug ApplicationSuhas Reddy C
 
controlled drug delivery system classification
controlled drug delivery system classificationcontrolled drug delivery system classification
controlled drug delivery system classificationravipharmabwm
 

Tendances (20)

alternative methods for dissolution.pptx
alternative methods for dissolution.pptxalternative methods for dissolution.pptx
alternative methods for dissolution.pptx
 
Bioequivalence study
Bioequivalence studyBioequivalence study
Bioequivalence study
 
Formulation and evaluation of microspheres
Formulation and evaluation of microspheresFormulation and evaluation of microspheres
Formulation and evaluation of microspheres
 
Biopharmaceutical factors effecting bioavailability
Biopharmaceutical factors effecting bioavailabilityBiopharmaceutical factors effecting bioavailability
Biopharmaceutical factors effecting bioavailability
 
Biorelevant ppt
Biorelevant pptBiorelevant ppt
Biorelevant ppt
 
Formulation Approaches For Gastro Retentive Drug Delivery
Formulation Approaches For Gastro Retentive Drug DeliveryFormulation Approaches For Gastro Retentive Drug Delivery
Formulation Approaches For Gastro Retentive Drug Delivery
 
Outsourcing BA and BE to CRO
Outsourcing BA and BE to CROOutsourcing BA and BE to CRO
Outsourcing BA and BE to CRO
 
Drug interactions linked to transporters
Drug interactions linked to transportersDrug interactions linked to transporters
Drug interactions linked to transporters
 
Dissolution and drug release testing
Dissolution and drug release testingDissolution and drug release testing
Dissolution and drug release testing
 
Liposomes
LiposomesLiposomes
Liposomes
 
Sr or cr formulations
Sr or cr formulationsSr or cr formulations
Sr or cr formulations
 
Self micro-emulsifying drug delivery system (SMEDDS)
Self micro-emulsifying drug delivery system (SMEDDS)Self micro-emulsifying drug delivery system (SMEDDS)
Self micro-emulsifying drug delivery system (SMEDDS)
 
Bioelectronic medicines
Bioelectronic medicinesBioelectronic medicines
Bioelectronic medicines
 
Drug product performance
Drug product performanceDrug product performance
Drug product performance
 
Biopharmaceutical system , methods of permeability , generic biologics, gener...
Biopharmaceutical system , methods of permeability , generic biologics, gener...Biopharmaceutical system , methods of permeability , generic biologics, gener...
Biopharmaceutical system , methods of permeability , generic biologics, gener...
 
Invitro invivo insitu method
Invitro invivo insitu methodInvitro invivo insitu method
Invitro invivo insitu method
 
Study submission of Bioequivalence and Drug review Process, BCS (BIOPHARMACEU...
Study submission of Bioequivalence and Drug review Process, BCS (BIOPHARMACEU...Study submission of Bioequivalence and Drug review Process, BCS (BIOPHARMACEU...
Study submission of Bioequivalence and Drug review Process, BCS (BIOPHARMACEU...
 
Pulmonary drug delivery system [PDDS]
Pulmonary drug delivery system [PDDS]Pulmonary drug delivery system [PDDS]
Pulmonary drug delivery system [PDDS]
 
Investigational New Drug Application
Investigational New Drug ApplicationInvestigational New Drug Application
Investigational New Drug Application
 
controlled drug delivery system classification
controlled drug delivery system classificationcontrolled drug delivery system classification
controlled drug delivery system classification
 

Similaire à Caco2 final ppt.

Caco-2 cell permeability assay for drug absorption
Caco-2 cell permeability assay for drug absorptionCaco-2 cell permeability assay for drug absorption
Caco-2 cell permeability assay for drug absorptionPHARMA IQ EDUCATION
 
Caco 2 cell permeability assay
Caco 2 cell permeability assayCaco 2 cell permeability assay
Caco 2 cell permeability assayCreative-Bioarray
 
Caco 2 Cell Permeability Assay
Caco 2 Cell Permeability AssayCaco 2 Cell Permeability Assay
Caco 2 Cell Permeability AssayCreative-Bioarray
 
drug product performance invivo
 drug product performance invivo drug product performance invivo
drug product performance invivoSUJITHA MARY
 
methods of determining drug absorption ppt
methods of determining drug absorption pptmethods of determining drug absorption ppt
methods of determining drug absorption ppttenzin jangchuk
 
Presentation1 riya pfd 1q
Presentation1 riya pfd 1qPresentation1 riya pfd 1q
Presentation1 riya pfd 1qRIYA PATEL
 
LPDT_A_938857-2014
LPDT_A_938857-2014LPDT_A_938857-2014
LPDT_A_938857-2014Mansi Shah
 
RADIOACTIVE PPT.pptx
RADIOACTIVE PPT.pptxRADIOACTIVE PPT.pptx
RADIOACTIVE PPT.pptxritikagaur16
 
Lusk_ceftriaxone_ASMS_2016_23May16
Lusk_ceftriaxone_ASMS_2016_23May16Lusk_ceftriaxone_ASMS_2016_23May16
Lusk_ceftriaxone_ASMS_2016_23May16Todd Lusk
 
Final Mycrobacteriophages Article
Final Mycrobacteriophages ArticleFinal Mycrobacteriophages Article
Final Mycrobacteriophages Articlejosearzon99
 

Similaire à Caco2 final ppt. (20)

Caco-2 cell permeability assay for drug absorption
Caco-2 cell permeability assay for drug absorptionCaco-2 cell permeability assay for drug absorption
Caco-2 cell permeability assay for drug absorption
 
Caco 2 cell permeability assay
Caco 2 cell permeability assayCaco 2 cell permeability assay
Caco 2 cell permeability assay
 
Caco 2 Cell Permeability Assay
Caco 2 Cell Permeability AssayCaco 2 Cell Permeability Assay
Caco 2 Cell Permeability Assay
 
drug product performance invivo
 drug product performance invivo drug product performance invivo
drug product performance invivo
 
methods of determining drug absorption ppt
methods of determining drug absorption pptmethods of determining drug absorption ppt
methods of determining drug absorption ppt
 
Mechanistic Studies of in vitro Anti- Proliferative Potential of Arisaena int...
Mechanistic Studies of in vitro Anti- Proliferative Potential of Arisaena int...Mechanistic Studies of in vitro Anti- Proliferative Potential of Arisaena int...
Mechanistic Studies of in vitro Anti- Proliferative Potential of Arisaena int...
 
Presentation1 riya pfd 1q
Presentation1 riya pfd 1qPresentation1 riya pfd 1q
Presentation1 riya pfd 1q
 
LPDT_A_938857-2014
LPDT_A_938857-2014LPDT_A_938857-2014
LPDT_A_938857-2014
 
PDF Article Filtration
PDF Article FiltrationPDF Article Filtration
PDF Article Filtration
 
cell Viability princes
cell Viability  princescell Viability  princes
cell Viability princes
 
RADIOACTIVE PPT.pptx
RADIOACTIVE PPT.pptxRADIOACTIVE PPT.pptx
RADIOACTIVE PPT.pptx
 
ApoB Sequencing
ApoB SequencingApoB Sequencing
ApoB Sequencing
 
Mammalian project poster
Mammalian project posterMammalian project poster
Mammalian project poster
 
JBS 2010
JBS 2010JBS 2010
JBS 2010
 
131116 paper study 준섭
131116 paper study 준섭131116 paper study 준섭
131116 paper study 준섭
 
Lusk_ceftriaxone_ASMS_2016_23May16
Lusk_ceftriaxone_ASMS_2016_23May16Lusk_ceftriaxone_ASMS_2016_23May16
Lusk_ceftriaxone_ASMS_2016_23May16
 
Final Mycrobacteriophages Article
Final Mycrobacteriophages ArticleFinal Mycrobacteriophages Article
Final Mycrobacteriophages Article
 
131116 paper study 준섭
131116 paper study 준섭131116 paper study 준섭
131116 paper study 준섭
 
131116 paper study 준섭
131116 paper study 준섭131116 paper study 준섭
131116 paper study 준섭
 
Resealed erythrocytes
Resealed erythrocytesResealed erythrocytes
Resealed erythrocytes
 

Dernier

Apidays New York 2024 - Accelerating FinTech Innovation by Vasa Krishnan, Fin...
Apidays New York 2024 - Accelerating FinTech Innovation by Vasa Krishnan, Fin...Apidays New York 2024 - Accelerating FinTech Innovation by Vasa Krishnan, Fin...
Apidays New York 2024 - Accelerating FinTech Innovation by Vasa Krishnan, Fin...apidays
 
ICT role in 21st century education and its challenges
ICT role in 21st century education and its challengesICT role in 21st century education and its challenges
ICT role in 21st century education and its challengesrafiqahmad00786416
 
ProductAnonymous-April2024-WinProductDiscovery-MelissaKlemke
ProductAnonymous-April2024-WinProductDiscovery-MelissaKlemkeProductAnonymous-April2024-WinProductDiscovery-MelissaKlemke
ProductAnonymous-April2024-WinProductDiscovery-MelissaKlemkeProduct Anonymous
 
Architecting Cloud Native Applications
Architecting Cloud Native ApplicationsArchitecting Cloud Native Applications
Architecting Cloud Native ApplicationsWSO2
 
WSO2's API Vision: Unifying Control, Empowering Developers
WSO2's API Vision: Unifying Control, Empowering DevelopersWSO2's API Vision: Unifying Control, Empowering Developers
WSO2's API Vision: Unifying Control, Empowering DevelopersWSO2
 
[BuildWithAI] Introduction to Gemini.pdf
[BuildWithAI] Introduction to Gemini.pdf[BuildWithAI] Introduction to Gemini.pdf
[BuildWithAI] Introduction to Gemini.pdfSandro Moreira
 
DBX First Quarter 2024 Investor Presentation
DBX First Quarter 2024 Investor PresentationDBX First Quarter 2024 Investor Presentation
DBX First Quarter 2024 Investor PresentationDropbox
 
AWS Community Day CPH - Three problems of Terraform
AWS Community Day CPH - Three problems of TerraformAWS Community Day CPH - Three problems of Terraform
AWS Community Day CPH - Three problems of TerraformAndrey Devyatkin
 
Platformless Horizons for Digital Adaptability
Platformless Horizons for Digital AdaptabilityPlatformless Horizons for Digital Adaptability
Platformless Horizons for Digital AdaptabilityWSO2
 
Connector Corner: Accelerate revenue generation using UiPath API-centric busi...
Connector Corner: Accelerate revenue generation using UiPath API-centric busi...Connector Corner: Accelerate revenue generation using UiPath API-centric busi...
Connector Corner: Accelerate revenue generation using UiPath API-centric busi...DianaGray10
 
Apidays New York 2024 - The Good, the Bad and the Governed by David O'Neill, ...
Apidays New York 2024 - The Good, the Bad and the Governed by David O'Neill, ...Apidays New York 2024 - The Good, the Bad and the Governed by David O'Neill, ...
Apidays New York 2024 - The Good, the Bad and the Governed by David O'Neill, ...apidays
 
Navigating the Deluge_ Dubai Floods and the Resilience of Dubai International...
Navigating the Deluge_ Dubai Floods and the Resilience of Dubai International...Navigating the Deluge_ Dubai Floods and the Resilience of Dubai International...
Navigating the Deluge_ Dubai Floods and the Resilience of Dubai International...Orbitshub
 
Six Myths about Ontologies: The Basics of Formal Ontology
Six Myths about Ontologies: The Basics of Formal OntologySix Myths about Ontologies: The Basics of Formal Ontology
Six Myths about Ontologies: The Basics of Formal Ontologyjohnbeverley2021
 
Strategies for Landing an Oracle DBA Job as a Fresher
Strategies for Landing an Oracle DBA Job as a FresherStrategies for Landing an Oracle DBA Job as a Fresher
Strategies for Landing an Oracle DBA Job as a FresherRemote DBA Services
 
MS Copilot expands with MS Graph connectors
MS Copilot expands with MS Graph connectorsMS Copilot expands with MS Graph connectors
MS Copilot expands with MS Graph connectorsNanddeep Nachan
 
Boost Fertility New Invention Ups Success Rates.pdf
Boost Fertility New Invention Ups Success Rates.pdfBoost Fertility New Invention Ups Success Rates.pdf
Boost Fertility New Invention Ups Success Rates.pdfsudhanshuwaghmare1
 
Elevate Developer Efficiency & build GenAI Application with Amazon Q​
Elevate Developer Efficiency & build GenAI Application with Amazon Q​Elevate Developer Efficiency & build GenAI Application with Amazon Q​
Elevate Developer Efficiency & build GenAI Application with Amazon Q​Bhuvaneswari Subramani
 
Cloud Frontiers: A Deep Dive into Serverless Spatial Data and FME
Cloud Frontiers:  A Deep Dive into Serverless Spatial Data and FMECloud Frontiers:  A Deep Dive into Serverless Spatial Data and FME
Cloud Frontiers: A Deep Dive into Serverless Spatial Data and FMESafe Software
 
MINDCTI Revenue Release Quarter One 2024
MINDCTI Revenue Release Quarter One 2024MINDCTI Revenue Release Quarter One 2024
MINDCTI Revenue Release Quarter One 2024MIND CTI
 
Apidays New York 2024 - Scaling API-first by Ian Reasor and Radu Cotescu, Adobe
Apidays New York 2024 - Scaling API-first by Ian Reasor and Radu Cotescu, AdobeApidays New York 2024 - Scaling API-first by Ian Reasor and Radu Cotescu, Adobe
Apidays New York 2024 - Scaling API-first by Ian Reasor and Radu Cotescu, Adobeapidays
 

Dernier (20)

Apidays New York 2024 - Accelerating FinTech Innovation by Vasa Krishnan, Fin...
Apidays New York 2024 - Accelerating FinTech Innovation by Vasa Krishnan, Fin...Apidays New York 2024 - Accelerating FinTech Innovation by Vasa Krishnan, Fin...
Apidays New York 2024 - Accelerating FinTech Innovation by Vasa Krishnan, Fin...
 
ICT role in 21st century education and its challenges
ICT role in 21st century education and its challengesICT role in 21st century education and its challenges
ICT role in 21st century education and its challenges
 
ProductAnonymous-April2024-WinProductDiscovery-MelissaKlemke
ProductAnonymous-April2024-WinProductDiscovery-MelissaKlemkeProductAnonymous-April2024-WinProductDiscovery-MelissaKlemke
ProductAnonymous-April2024-WinProductDiscovery-MelissaKlemke
 
Architecting Cloud Native Applications
Architecting Cloud Native ApplicationsArchitecting Cloud Native Applications
Architecting Cloud Native Applications
 
WSO2's API Vision: Unifying Control, Empowering Developers
WSO2's API Vision: Unifying Control, Empowering DevelopersWSO2's API Vision: Unifying Control, Empowering Developers
WSO2's API Vision: Unifying Control, Empowering Developers
 
[BuildWithAI] Introduction to Gemini.pdf
[BuildWithAI] Introduction to Gemini.pdf[BuildWithAI] Introduction to Gemini.pdf
[BuildWithAI] Introduction to Gemini.pdf
 
DBX First Quarter 2024 Investor Presentation
DBX First Quarter 2024 Investor PresentationDBX First Quarter 2024 Investor Presentation
DBX First Quarter 2024 Investor Presentation
 
AWS Community Day CPH - Three problems of Terraform
AWS Community Day CPH - Three problems of TerraformAWS Community Day CPH - Three problems of Terraform
AWS Community Day CPH - Three problems of Terraform
 
Platformless Horizons for Digital Adaptability
Platformless Horizons for Digital AdaptabilityPlatformless Horizons for Digital Adaptability
Platformless Horizons for Digital Adaptability
 
Connector Corner: Accelerate revenue generation using UiPath API-centric busi...
Connector Corner: Accelerate revenue generation using UiPath API-centric busi...Connector Corner: Accelerate revenue generation using UiPath API-centric busi...
Connector Corner: Accelerate revenue generation using UiPath API-centric busi...
 
Apidays New York 2024 - The Good, the Bad and the Governed by David O'Neill, ...
Apidays New York 2024 - The Good, the Bad and the Governed by David O'Neill, ...Apidays New York 2024 - The Good, the Bad and the Governed by David O'Neill, ...
Apidays New York 2024 - The Good, the Bad and the Governed by David O'Neill, ...
 
Navigating the Deluge_ Dubai Floods and the Resilience of Dubai International...
Navigating the Deluge_ Dubai Floods and the Resilience of Dubai International...Navigating the Deluge_ Dubai Floods and the Resilience of Dubai International...
Navigating the Deluge_ Dubai Floods and the Resilience of Dubai International...
 
Six Myths about Ontologies: The Basics of Formal Ontology
Six Myths about Ontologies: The Basics of Formal OntologySix Myths about Ontologies: The Basics of Formal Ontology
Six Myths about Ontologies: The Basics of Formal Ontology
 
Strategies for Landing an Oracle DBA Job as a Fresher
Strategies for Landing an Oracle DBA Job as a FresherStrategies for Landing an Oracle DBA Job as a Fresher
Strategies for Landing an Oracle DBA Job as a Fresher
 
MS Copilot expands with MS Graph connectors
MS Copilot expands with MS Graph connectorsMS Copilot expands with MS Graph connectors
MS Copilot expands with MS Graph connectors
 
Boost Fertility New Invention Ups Success Rates.pdf
Boost Fertility New Invention Ups Success Rates.pdfBoost Fertility New Invention Ups Success Rates.pdf
Boost Fertility New Invention Ups Success Rates.pdf
 
Elevate Developer Efficiency & build GenAI Application with Amazon Q​
Elevate Developer Efficiency & build GenAI Application with Amazon Q​Elevate Developer Efficiency & build GenAI Application with Amazon Q​
Elevate Developer Efficiency & build GenAI Application with Amazon Q​
 
Cloud Frontiers: A Deep Dive into Serverless Spatial Data and FME
Cloud Frontiers:  A Deep Dive into Serverless Spatial Data and FMECloud Frontiers:  A Deep Dive into Serverless Spatial Data and FME
Cloud Frontiers: A Deep Dive into Serverless Spatial Data and FME
 
MINDCTI Revenue Release Quarter One 2024
MINDCTI Revenue Release Quarter One 2024MINDCTI Revenue Release Quarter One 2024
MINDCTI Revenue Release Quarter One 2024
 
Apidays New York 2024 - Scaling API-first by Ian Reasor and Radu Cotescu, Adobe
Apidays New York 2024 - Scaling API-first by Ian Reasor and Radu Cotescu, AdobeApidays New York 2024 - Scaling API-first by Ian Reasor and Radu Cotescu, Adobe
Apidays New York 2024 - Scaling API-first by Ian Reasor and Radu Cotescu, Adobe
 

Caco2 final ppt.

  • 1. A SEMINAR ONTRANSPORT ACROSS CACO-2 MONOLAYER GUIDED BY:BY: PATEL AKSHAY DR.MANISH PATEL M.PHARM- 1(ph’ceutics) (head of department) ROLL NO-05 Department of Pharmaceutics NOOTAN PHARMACY COLLEGE,VISNAGAR
  • 2.
  • 11.
  • 12. Intestinal Absorption: Biology Enterocite biology: Absorptive cells of intestine, function is terminal digestion and absorption of water and nutrients from the intestinal lumen. Polarised monolayer : -Apical: microvilli face the interior of gut and increase the surface available for absorption by>1000 fold -Basal: faces away from gut in contact with extracellular matrix.
  • 13.
  • 14.
  • 15. B: carrier mediated absorption at apical and basolateral membranes;
  • 16. C: active efflux transporter on apical membrane, acting during absorption;
  • 17. D: active efflux transporter on apical membrane, offering an additional route for drug clearance from the circulation;
  • 18.
  • 19.
  • 20. HT 29 Cells: Colon carcinoma, cultured with galactose, express mucus producing goblet cells differenciation
  • 21.
  • 22.
  • 23. Four times higher in transepithelial resistance compared to HT 29-cell monolayer
  • 24.
  • 25. Dose not produce the mucus and unstirred water Observed in the intestine
  • 26. No P-450 drug metabolizing enzyme activity has been reported
  • 28. Time consuming as 21 days required for full cell differentiation
  • 29. The necessity of LC / MS or HPLC for quantitation
  • 30.
  • 33. Characterization of cell monolayer Cellular Architecture (Microvilli, Junctional Complexes) Barrier Function ( Lucifer Yellow Permeability, TEER) Differentiation Markers (Alkaline Phosphate, Brush-Border Peptidases) Transporters (P-Glycoprotein, PepT1, Amino acid Transporter, glucose)
  • 35.
  • 36. 4. The measurement chamber was tempered to 37°C with transport medium before the measurement. For the post-experimental TEER measurement, the withdrawn volume in the apical compartment was replaced with transport medium before TEER was measured. 5.Caco-2 monolayer with TEER values exceeding 250 Ωcm2 were used for transport experiments. 6. Background TEER may be recorded in wells without cell monolayers, and can be subtracted from the raw TEER values with cells.
  • 37. B. Lucifer yellow (LY) rejection: Rinse the monolayer three times with 300 µL HBSS ( Hank’s buffer saline solution) in the apical wells and 28 mL in the feeder tray. Add 300 µL of LY solution to each well in the filter plate (Apical Template). Add 600 µL HBSS to each well of a 24-well receiver tray (Basolateral Template). Assemble the filter plate and 24-well receiver plate and incubate for 1–2 hours at 37°C. Remove the filter plate from the receiver plate and place the receiver plate into a fluorescent plate reader. Determine the LY fluorescence using an excitation wavelength of 425-430 nm and an emission wavelength of 515-520 nm, 540 nm.
  • 38. Calculate the percent of LY rejection across the cell monolayer by measuring fluorescence in the receiver plate as compared to an ‘equilibrium’ standard.The standard plate should consist of 4 wells with 600 µL HBSS (blank) and 4 wells with 200 µL LY (100 µg/mL) + 400 µL HBSS (equilibrium samples)Calculate the LY rejection using the following equation: LY Rejection=100%-%LY Passage
  • 39. Caco-2 Permeability Assay Procedure: After the desired cell growth period, remove the plate from the incubator and determine the electrical resistance for each well (as described above). Wash the monolayer, exchanging the volume three times using sterile HBSS, pH 7.4. After washing, remove the buffer from the filter plate and feeder tray. Transfer the filter plate to a 24-well transport analysis plate. To determine the rate of drug transport in the apical to basolateral direction, add 300 µL of the test compounds to the filter well. Drug concentrations typically ranging from 10 µm to 200 µm may be used (achieve desired concentration using HBSS, pH 7.4 or an alternative buffer of desired pH). Fill the wells of the 24-well receiver plate with 600 µL buffer. To determine the rate of drug transport in the basolateral to apical direction, add 600 µL of the test compounds to the 24-well receiver plate.
  • 40. Fill the filter wells (apical compartment) with 300 µL of buffer. Join the filter and receiver plates once all drugs and buffer have been added. Begin timing the experiment. Incubate at 37°C shaking at 60 rpm on a rotary shaker. Typical incubation times are 1 to 2 hours. For LC/MS analysis: At the end of the incubation, remove a fixed volume (typically 50–100 µL) directly from the apical and basolateral wells (using the basolateral access holes) or by disassembling the plates. Transfer the volume to a clean plate.
  • 41.
  • 42.
  • 43.
  • 44.
  • 45. Biological pharmaceutical and analytical consideration
  • 47.
  • 48.
  • 49.
  • 50. 4) To study transport mechanism fro many compounds
  • 51. 5) In drug metabolism & toxicity effects.
  • 52.
  • 53.
  • 54.
  • 55.
  • 56. Good correlationbetween PAMPA & caco-2 data for a compound indicates a predominance ofpassive diffusion in its permeation.
  • 58. absorptive (active, paracellular ,gradient effect for acids) or
  • 59.
  • 60.
  • 61.
  • 62. MDCK cell lines originate from dogkidney.
  • 63.
  • 64.